Drug Profile
Research programme: anti-interleukin-22 monoclonal antibodies - BioAtla/BioMotiv
Alternative Names: anti-IL-22 monoclonal antibodies - BioAtla/BioMotiv; IL-22 antibodies - BioAlta/BioMotiv; Interleukin-22 antibodies - BioAtla/BioMotivLatest Information Update: 28 Mar 2018
Price :
$50
*
At a glance
- Originator BioAtla
- Developer BioMotiv
- Class Monoclonal antibodies
- Mechanism of Action Interleukin-22 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inflammatory bowel diseases
Most Recent Events
- 28 Mar 2018 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 28 Mar 2018 No recent reports of development identified for research development in Inflammatory-bowel-disease in USA (Parenteral)
- 19 Feb 2014 BioMotiv acquires anti-IL-22 monoclonal antibodies from BioAtla